Cargando…

A Light-Driven Therapy of Pancreatic Adenocarcinoma Using Gold Nanorods-Based Nanocarriers for Co-Delivery of Doxorubicin and siRNA

In this work, we report the engineering of polyelectrolyte polymers coated Gold nanorods (AuNRs)-based nanocarriers that are capable of co-delivering small interfering RNA (siRNA) and an anticancer drug doxorubicin (DOX) to Panc-1 cancer cells for combination of both chemo- and siRNA-mediated mutant...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Feng, Yang, Chengbin, Wang, Qianqian, Zeng, Shuwen, Hu, Rui, Lin, Guimiao, Tian, Jinglin, Hu, Siyi, Lan, Rong Feng, Yoon, Ho Sup, Lu, Fei, Wang, Kuan, Yong, Ken-Tye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440440/
https://www.ncbi.nlm.nih.gov/pubmed/26000055
http://dx.doi.org/10.7150/thno.11335
_version_ 1782372640297582592
author Yin, Feng
Yang, Chengbin
Wang, Qianqian
Zeng, Shuwen
Hu, Rui
Lin, Guimiao
Tian, Jinglin
Hu, Siyi
Lan, Rong Feng
Yoon, Ho Sup
Lu, Fei
Wang, Kuan
Yong, Ken-Tye
author_facet Yin, Feng
Yang, Chengbin
Wang, Qianqian
Zeng, Shuwen
Hu, Rui
Lin, Guimiao
Tian, Jinglin
Hu, Siyi
Lan, Rong Feng
Yoon, Ho Sup
Lu, Fei
Wang, Kuan
Yong, Ken-Tye
author_sort Yin, Feng
collection PubMed
description In this work, we report the engineering of polyelectrolyte polymers coated Gold nanorods (AuNRs)-based nanocarriers that are capable of co-delivering small interfering RNA (siRNA) and an anticancer drug doxorubicin (DOX) to Panc-1 cancer cells for combination of both chemo- and siRNA-mediated mutant K-Ras gene silencing therapy. Superior anticancer efficacy was observed through synergistic combination of promoted siRNA and DOX release upon irradiating the nanoplex formulation with 665 nm light. Our antitumor study shows that the synergistic effect of AuNRs nanoplex formulation with 665 nm light treatment is able to inhibit the in vivo tumor volume growth rate by 90%. The antitumor effect is contributed from the inactivation of K-Ras gene and thereby causing a profound synthesis (S) phase arrest in treated Panc-1 cells. Our study shows that the percentage of Panc-1 cells treated by nanoplex formulation with S phase is determined to be 35% and it is 17% much higher than that of Panc-1 cells without any treatments. The developed nanotherapy formulation here, that combines chemotherapy, RNA silencing and NIR window light-mediated therapy, will be seen to be the next natural step to be taken in the clinical research for improving the therapeutic outcomes of the pancreatic adenocarcinoma treatment.
format Online
Article
Text
id pubmed-4440440
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-44404402015-05-21 A Light-Driven Therapy of Pancreatic Adenocarcinoma Using Gold Nanorods-Based Nanocarriers for Co-Delivery of Doxorubicin and siRNA Yin, Feng Yang, Chengbin Wang, Qianqian Zeng, Shuwen Hu, Rui Lin, Guimiao Tian, Jinglin Hu, Siyi Lan, Rong Feng Yoon, Ho Sup Lu, Fei Wang, Kuan Yong, Ken-Tye Theranostics Research Paper In this work, we report the engineering of polyelectrolyte polymers coated Gold nanorods (AuNRs)-based nanocarriers that are capable of co-delivering small interfering RNA (siRNA) and an anticancer drug doxorubicin (DOX) to Panc-1 cancer cells for combination of both chemo- and siRNA-mediated mutant K-Ras gene silencing therapy. Superior anticancer efficacy was observed through synergistic combination of promoted siRNA and DOX release upon irradiating the nanoplex formulation with 665 nm light. Our antitumor study shows that the synergistic effect of AuNRs nanoplex formulation with 665 nm light treatment is able to inhibit the in vivo tumor volume growth rate by 90%. The antitumor effect is contributed from the inactivation of K-Ras gene and thereby causing a profound synthesis (S) phase arrest in treated Panc-1 cells. Our study shows that the percentage of Panc-1 cells treated by nanoplex formulation with S phase is determined to be 35% and it is 17% much higher than that of Panc-1 cells without any treatments. The developed nanotherapy formulation here, that combines chemotherapy, RNA silencing and NIR window light-mediated therapy, will be seen to be the next natural step to be taken in the clinical research for improving the therapeutic outcomes of the pancreatic adenocarcinoma treatment. Ivyspring International Publisher 2015-04-20 /pmc/articles/PMC4440440/ /pubmed/26000055 http://dx.doi.org/10.7150/thno.11335 Text en © 2015 Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions.
spellingShingle Research Paper
Yin, Feng
Yang, Chengbin
Wang, Qianqian
Zeng, Shuwen
Hu, Rui
Lin, Guimiao
Tian, Jinglin
Hu, Siyi
Lan, Rong Feng
Yoon, Ho Sup
Lu, Fei
Wang, Kuan
Yong, Ken-Tye
A Light-Driven Therapy of Pancreatic Adenocarcinoma Using Gold Nanorods-Based Nanocarriers for Co-Delivery of Doxorubicin and siRNA
title A Light-Driven Therapy of Pancreatic Adenocarcinoma Using Gold Nanorods-Based Nanocarriers for Co-Delivery of Doxorubicin and siRNA
title_full A Light-Driven Therapy of Pancreatic Adenocarcinoma Using Gold Nanorods-Based Nanocarriers for Co-Delivery of Doxorubicin and siRNA
title_fullStr A Light-Driven Therapy of Pancreatic Adenocarcinoma Using Gold Nanorods-Based Nanocarriers for Co-Delivery of Doxorubicin and siRNA
title_full_unstemmed A Light-Driven Therapy of Pancreatic Adenocarcinoma Using Gold Nanorods-Based Nanocarriers for Co-Delivery of Doxorubicin and siRNA
title_short A Light-Driven Therapy of Pancreatic Adenocarcinoma Using Gold Nanorods-Based Nanocarriers for Co-Delivery of Doxorubicin and siRNA
title_sort light-driven therapy of pancreatic adenocarcinoma using gold nanorods-based nanocarriers for co-delivery of doxorubicin and sirna
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440440/
https://www.ncbi.nlm.nih.gov/pubmed/26000055
http://dx.doi.org/10.7150/thno.11335
work_keys_str_mv AT yinfeng alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna
AT yangchengbin alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna
AT wangqianqian alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna
AT zengshuwen alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna
AT hurui alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna
AT linguimiao alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna
AT tianjinglin alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna
AT husiyi alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna
AT lanrongfeng alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna
AT yoonhosup alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna
AT lufei alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna
AT wangkuan alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna
AT yongkentye alightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna
AT yinfeng lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna
AT yangchengbin lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna
AT wangqianqian lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna
AT zengshuwen lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna
AT hurui lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna
AT linguimiao lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna
AT tianjinglin lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna
AT husiyi lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna
AT lanrongfeng lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna
AT yoonhosup lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna
AT lufei lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna
AT wangkuan lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna
AT yongkentye lightdriventherapyofpancreaticadenocarcinomausinggoldnanorodsbasednanocarriersforcodeliveryofdoxorubicinandsirna